A Phase 3 interventional study of Plecanatide and Placebo in Chronic Idiopathic Constipation, sponsored by Bausch Health Americas, Inc.. Completed at 167 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-05-28.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing plecanatide in Constipation — none open to participants now, 1 under way, none of them phase 3. plecanatide · Constipation.
Among the 12 studies testing plecanatide in Constipation, this one is the 2nd largest by enrollment, is one of 2 that started in 2014, is one of 6 in phase 3, and was the 6th registered.
1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.
Browse Constipation studies →None of the 12 studies testing plecanatide in Constipation is open now. The open studies under Constipation, anywhere →
plecanatide: first FDA approval 2017 (TRULANCE). What it is approved for, and how studies give it, is on its page →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 7
First in 2010; this study’s year is marked. 2 started in 2014.
This study's enrollment of 1,410 is above the median of 75 across 885 interventional studies indexed under Constipation.
Median enrollment 800 across the 12 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 2 most frequent:
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
21 studies in Constipation by Bausch Health Companies Inc.: none open now, 1 under way, none of them phase 3. Of 20 finished, 15 (75%) have results posted.
Among the 21 studies in Constipation by Bausch Health Companies Inc., this one is the 2nd largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2014, is one of 8 in phase 3, and was the 15th registered.
Bausch Health Companies Inc.’s Constipation studies by the year they started, since 2006.
1 of the studies testing plecanatide in Constipation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07723924Bausch Health Americas, Inc.This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC | 2027-10-18 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing plecanatide in Constipation, from their registry updates:
Among Bausch Health Companies Inc.’s 21 in Constipation:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to confirm that the investigational medication, plecanatide, is safe and effective in treating chronic idiopathic constipation.
This is a national, randomized, 12-week, double-blind, placebo-controlled, study in approximately 1350 adult male and female patients with CIC comparing 2 doses of plecanatide to placebo. The study will be conducted at approximately 180 clinical study sites in the United States. The primary objective of the study is to evaluate the efficacy and safety of 3.0 and 6.0 mg of plecanatide administered once daily (QD) for 12 weeks in a population of patients with CIC. The study population will include only patients without other causes of constipation or other chronic conditions that could interfere with study assessments. Patients may not take laxatives (with the exception of the study-provided rescue medication, bisacodyl 5mg tablets), or a number of prohibited drugs that are known to cause constipation or diarrhea, during study participation.
There are 6 scheduled study visits, including the screening and follow-up visits. The planned duration of participation in this study will be 112 days and up to 155 days, with washout and all visit windows considered.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Plecanatide tablets 3.0 mg QD for 12 weeks
Drug: Plecanatide
Matching placebo tablets QD for 12 weeks
Drug: Placebo
Plecanatide tablets 6.0 mg QD for 12 weeks
Drug: Plecanatide
Number of Durable Overall CSBM Responders, Mean Replacement Approach
The primary efficacy endpoint was measured by the number of durable overall CSBM responders over the 12-week Treatment Period. A durable overall CSBM responder was defined as a weekly CSBM responder for at least 9 of the 12 treatment weeks, including at least 3 of the last 4 weeks. A CSBM weekly responder was defined as a patient who has ≥ 3 Complete Spontaneous Bowel Movements (CSBMs) per week and an increase from baseline of ≥1 CSBM for that week. A CSBM was a bowel movement that occurred in the absence of laxative use within 24 hours and was associated with the feeling of complete evacuation.
Time frame: 12-Week Treatment Period
Change From Baseline in CSBMs (CSBMs/Week) Over the 12-week Treatment Period , Mean Replacement Approach
The change from baseline in the number of Complete Spontaneous Bowel Movements (CSBMs) over the 12-week Treatment Period was analyzed. Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. A CSBM was a bowel movement that occurred in the absence of laxative use within 24 hours and was associated with the feeling of complete evacuation.
Time frame: Baseline and 12 weeks
Change From Baseline in SBMs (SBMs/Week) Over the 12-week Treatment Period, Mean Replacement Approach
The change from baseline in the number of Spontaneous Bowel Movement (SBM) over the 12-week Treatment Period was analyzed. Baseline was the mean number of SBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly SBM totals were derived from the daily diary entries reported during the Treatment Period.
Time frame: Baseline and 12 weeks
Change From Baseline in Average Weekly SBM Stool Consistency Over the 12-week Treatment Period, Mean Replacement Approach
The change from baseline in the stool consistency score (i.e. BSFS) over the 12-week Treatment Period was analyzed. Baseline was the mean BSFS score recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly mean BSFS score per patient was derived from the BSFS entries reported during the Treatment Period in the Daily Symptom Diary. The stool consistency of each bowel movement (BM) was assessed by patients using the 7-point Bristol Stool Form Scale \[BSFS\] from 1 to 7. 1. = separate hard lumps like nuts (difficult to pass) 2. = sausage shaped but lumpy 3. = like a sausage but with cracks on its surface 4. = like a sausage or snake, smooth and soft 5. = soft blobs with clear-cut edges (passed easily) 6. = fluffy pieces with ragged edges, a mushy stool 7. = watery, no solid pieces (entirely liquid)
Time frame: Baseline and 12 weeks
Change From Baseline in Average Weekly Straining Score Over the 12-week Treatment Period, Mean Replacement Approach
The change from baseline in the straining score over the 12-week Treatment Period was analyzed. Baseline was the mean of non-missing straining scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly average straining score was derived from the straining scores reported during the Treatment Period in the Daily Symptom Diary. The severity of straining during bowel movements was assessed on a 5-point Likert scale where 0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.
Time frame: Baseline and 12 weeks
| Milestone | Placebo | Plecanatide 3 mg | Plecanatide 6 mg |
|---|---|---|---|
| Started | 445 | 443 | 449 |
| Completed | 406 | 392 | 405 |
| Not completed | 39 | 51 | 44 |
The primary efficacy endpoint was measured by the number of durable overall CSBM responders over the 12-week Treatment Period. A durable overall CSBM responder was defined as a weekly CSBM responder for at least 9 of the 12 treatment weeks, including at least 3 of the last 4 weeks. A CSBM weekly responder was defined as a patient who has ≥ 3 Complete Spontaneous Bowel Movements (CSBMs) per week and an increase from baseline of ≥1 CSBM for that week. A CSBM was a bowel movement that occurred in the absence of laxative use within 24 hours and was associated with the feeling of complete evacuation.
| Participants | Placebo | Plecanatide 3 mg | Plecanatide 6 mg |
|---|---|---|---|
| Number of Durable Overall CSBM Responders, Mean Replacement Approach | 57 | 88 | 88 |
The change from baseline in the number of Complete Spontaneous Bowel Movements (CSBMs) over the 12-week Treatment Period was analyzed. Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. A CSBM was a bowel movement that occurred in the absence of laxative use within 24 hours and was associated with the feeling of complete evacuation.
| CSBMs per week | Placebo | Plecanatide 3 mg | Plecanatide 6 mg |
|---|---|---|---|
| Baseline | 1.41 ± 0.138 | 2.34 ± 0.139 | 2.19 ± 0.138 |
| 12 weeks | 1.69 ± 0.159 | 2.66 ± 0.162 | 2.50 ± 0.159 |
The change from baseline in the number of Spontaneous Bowel Movement (SBM) over the 12-week Treatment Period was analyzed. Baseline was the mean number of SBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly SBM totals were derived from the daily diary entries reported during the Treatment Period.
| SBMs per week | Placebo | Plecanatide 3 mg | Plecanatide 6 mg |
|---|---|---|---|
| Baseline | 1.55 ± 1.591 | 1.79 ± 2.084 | 1.63 ± 1.673 |
| 12 weeks | 1.81 ± 2.879 | 3.25 ± 3.938 | 3.10 ± 4.164 |
The change from baseline in the stool consistency score (i.e. BSFS) over the 12-week Treatment Period was analyzed. Baseline was the mean BSFS score recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly mean BSFS score per patient was derived from the BSFS entries reported during the Treatment Period in the Daily Symptom Diary. The stool consistency of each bowel movement (BM) was assessed by patients using the 7-point Bristol Stool Form Scale \[BSFS\] from 1 to 7. 1. = separate hard lumps like nuts (difficult to pass) 2. = sausage shaped but lumpy 3. = like a sausage but with cracks on its surface 4. = like a sausage or snake, smooth and soft 5. = soft blobs with clear-cut edges (passed easily) 6. = fluffy pieces with ragged edges, a mushy stool 7. = watery, no solid pieces (entirely liquid)
| score on a scale | Placebo | Plecanatide 3 mg | Plecanatide 6 mg |
|---|---|---|---|
| Baseline | 2.35 ± 1.090 | 2.16 ± 1.036 | 2.27 ± 1.113 |
| 12 weeks | 1.02 ± 1.346 | 1.71 ± 1.475 | 1.59 ± 1.497 |
The change from baseline in the straining score over the 12-week Treatment Period was analyzed. Baseline was the mean of non-missing straining scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly average straining score was derived from the straining scores reported during the Treatment Period in the Daily Symptom Diary. The severity of straining during bowel movements was assessed on a 5-point Likert scale where 0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.
| score on a scale | Placebo | Plecanatide 3 mg | Plecanatide 6 mg |
|---|---|---|---|
| Baseline | 2.42 ± 0.855 | 2.46 ± 0.859 | 2.47 ± 0.888 |
| 12 weeks | -0.79 ± 1.132 | -1.09 ± 1.092 | -1.04 ± 1.084 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 8/466 (1.7%) | 15/466 (3.2%) |
| Plecanatide 3 mg | — | 8/467 (1.7%) | 25/467 (5.4%) |
| Plecanatide 6 mg | — | 4/469 (0.9%) | 31/469 (6.6%) |
| Event | Placebo | Plecanatide 3 mg | Plecanatide 6 mg |
|---|---|---|---|
| Non-cardiac chest painGeneral disorders | 1/466 | 0/467 | 0/469 |
| Femoral neck fractureInjury, poisoning and procedural complications | 1/466 | 0/467 | 0/469 |
| Alanine aminotransferase increasedInvestigations | 1/466 | 0/467 | 0/469 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/466 | 0/467 | 0/469 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/466 | 0/467 | 0/469 |
| PregnancyPregnancy, puerperium and perinatal conditions | 1/466 | 1/467 | 1/469 |
| NephrolithiasisRenal and urinary disorders | 1/466 | 0/467 | 0/469 |
| Arterial occlusive diseaseVascular disorders | 1/466 | 0/467 | 0/469 |
| Cardiac failure congestiveCardiac disorders | 0/466 | 1/467 | 0/469 |
| Vertigo positionalEar and labyrinth disorders | 0/466 | 1/467 | 0/469 |
| Event | Placebo | Plecanatide 3 mg | Plecanatide 6 mg |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 6/466 | 15/467 | 21/469 |
| HeadacheNervous system disorders | 9/466 | 10/467 | 10/469 |
| Age, Continuous(years) | Placebo | Plecanatide 3 mg | Plecanatide 6 mg | Total |
|---|---|---|---|---|
| Mean | 44.6 ± 14.59 | 45.5 ± 14.38 | 45.3 ± 14.47 | 45.1 ± 14.47 |
| Sex: Female, Male(Participants) | Placebo | Plecanatide 3 mg | Plecanatide 6 mg | Total |
|---|---|---|---|---|
| Female | 350 | 345 | 353 | 1048 |
| Male | 95 | 98 | 96 | 289 |
Showing the first 100 of 167 sites. Choose a country and city above to see the rest.
The record gives a start of Apr 2014, a primary completion of May 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2019, 3 years 10 months after primary completion. A results delay was requested in Apr 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Plecanatide
Bausch Health Americas, Inc. →